Gallbladder disease, cholecystectomy, and pancreatic cancer risk in the International Pancreatic Cancer Case-Control Consortium (PanC4).
Por:
Rosato V, Negri E, Bosetti C, Malats N, Gomez-Rubio P, Consortium P, Maisonneuve P, Miller AB, Bueno-de-Mesquita HB, Baghurst PA, Zatonski W, Petersen GM, Scelo G, Holcatova I, Fabianova E, Serraino D, Olson SH, Vioque J, Lagiou P, Duell EJ, Boffetta P and La Vecchia C
Publicada:
1 sep 2020
Ahead of Print:
21 abr 2020
Resumen:
BACKGROUND: The association among gallbladder disease, cholecystectomy, and pancreatic cancer is unclear. Moreover, time interval between gallbladder disease or cholecystectomy and pancreatic cancer diagnosis is not considered in most previous studies. AIM: To quantify the association among gallbladder disease, cholecystectomy, and pancreatic cancer, considering time since first diagnosis of gallbladder disease or cholecystectomy. METHODS: We used data from nine case-control studies within the Pancreatic Cancer Case-Control Consortium, including 5760 cases of adenocarcinoma of the exocrine pancreas and 8437 controls. We estimated pooled odds ratios and the corresponding 95% confidence intervals by estimating study-specific odds ratios through multivariable unconditional logistic regression models, and then pooling the obtained estimates using fixed-effects models. RESULTS: Compared with patients with no history of gallbladder disease, the pooled odds ratio of pancreatic cancer was 1.69 (95% confidence interval, 1.51-1.88) for patients reporting a history of gallbladder disease. The odds ratio was 4.90 (95% confidence interval, 3.45-6.97) for gallbladder disease diagnosed <2 years before pancreatic cancer diagnosis and 1.11 (95% confidence interval, 0.96-1.29) when =2 years elapsed. The pooled odds ratio was 1.64 (95% confidence interval, 1.43-1.89) for patients who underwent cholecystectomy, as compared to those without cholecystectomy. The odds ratio was 7.00 (95% confidence interval, 4.13-11.86) for a surgery <2 years before pancreatic cancer diagnosis and 1.28 (95% confidence interval, 1.08-1.53) for a surgery =2 years before. CONCLUSIONS: There appears to be no long-term effect of gallbladder disease on pancreatic cancer risk, and at most a modest one for cholecystectomy. The strong short-term association can be explained by diagnostic bias and reverse causation.
Filiaciones:
Rosato V:
Unit of Medical Statistics and Biometry, National Cancer Institute, IRCCS Foundation
Negri E:
Department of Biomedical and Clinical Sciences, University of Milan
Bosetti C:
Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
Malats N:
Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO) and CIBERONC, Madrid, Spain
Gomez-Rubio P:
Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO) and CIBERONC, Madrid, Spain
Consortium P:
Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO) and CIBERONC, Madrid, Spain
Maisonneuve P:
Division of Epidemiology and Biostatistics, IEO European Institute of Oncology IRCCS, Milan, Italy
Miller AB:
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
Bueno-de-Mesquita HB:
National Institute for Public Health and the Environment (RIVM), Bilthoven
Department of Gastroenterology and Hepatology, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
Baghurst PA:
Public Health, Women's and Children's Hospital, Adelaide, South Australia, Australia
Zatonski W:
Health Promotion Foundation, Nadarzyn
Cancer Center and Institute of Oncology, Warsaw, Poland
Petersen GM:
Department of Health Sciences Research, Medicine and Medical Genetics, Mayo Clinic, Rochester, New York, USA
Scelo G:
International Agency for Research on Cancer (IARC), Lyon, France
Holcatova I:
Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
Fabianova E:
Regional Authority of Public Health, Banská Bystrica, Slovak Republic
Faculty of Health, Catholic University, Ružomberok, Slovak Republic
Serraino D:
Cancer Epidemiology Unit, National Cancer Institute Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
Olson SH:
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
:
Institute for Health and Biomedical Research ISABIAL-UMH, Alicante
CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain
Lagiou P:
Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, University of Athens, Athens, Greece
Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
Duell EJ:
Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
Boffetta P:
The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA
La Vecchia C:
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
Open Access
FULL TEXT
 |
Published Version |
|
| No Accesible |
|